10 Best Non-Tech Stocks to Buy Now for Long Term

Page 4 of 10

7. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 92 

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company reported full-year 2024 revenues of $63.6 billion, reflecting a 7% year-over-year operational growth; excluding contributions from Paxlovid and Comirnaty, revenues grew 12% operationally. In February, the firm announced positive results from its Phase 3 BREAKWATER study, showing that BRAFTOVI combined with cetuximab and mFOLFOX6 significantly improved progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The combination also showed meaningful improvements in overall survival (OS) compared to standard chemotherapy, with or without Bevacizumab, an anti-angiogenic cancer drug.

Page 4 of 10